Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

ABSTRACT: Tuberculosis (TB) is historically the world's deadliest infectious disease. New TB drugs that can avoid pre-existing resistance are desperately needed. The β-lactams are the oldest and most widely used class of antibiotics to treat bacterial infections but, for a variety of reasons, they were largely ignored until recently as a potential treatment option for TB. Recently, a growing body of evidence indicates that later-generation carbapenems in the presence of β-lactamase inhibitors could play a role in TB treatment. However, most of these drugs can only be administered intravenously in the clinic. We performed a screening of β-lactams against intracellular Mycobacterium tuberculosis (Mtb) and identified sanfetrinem cilexetil as a promising oral β-lactam candidate. Preclinica

SUBMITTER: Ramon-Garcia S 

PROVIDER: S-EPMC11722294 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature